melphalan and Pharyngeal-Neoplasms

In a human case of plasmacytoma we studied plasma and tumor concentrations of melphalan given intravenously. Intratumoral concentration of melphalan was similar to plasma concentration 60 min after the end of infusion.

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Injections, Intravenous; Male; Melphalan; Oropharyngeal Neoplasms; Pharyngeal Neoplasms; Plasmacytoma; Prednisolone

Open-field gamma-beam therapy using grid filters was used for 53 patients with Stage III-III stomatopharyngeal tumors. Besides, to compare therapeutic efficacy the 2nd group was taken (52 persons with Stage III-IV) where chemotherapy was used simultaneously. Single and summary radiation doses did not lower. A chemotherapeutic agent dose was equal to 1/2 up to 2/3 of the standard one. Powerful substitution and hemostimulation therapy and a great variety of drugs were employed not to induce deep changes of hemopoiesis and immunosuppression. A single focal dose in gamma-beam therapy varied from 1.6 to 2.5 Gy, the summary dose from 55 to 70 Gy depending on the stage of disease and the histological structure of a tumor. The prescription of one or another chemotherapeutic agent was mainly determined by the morphological structure of a tumor.

Topics: Adult; Aged; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Gamma Rays; Humans; Melphalan; Methotrexate; Middle Aged; Oropharyngeal Neoplasms; Pharyngeal Neoplasms; Prognosis; Sarcoma; Thiotepa